Kiniksa Pharmaceuticals International PLC (NAS:KNSA)
$ 22.32 0.28 (1.27%) Market Cap: 1.61 Bil Enterprise Value: 1.40 Bil PE Ratio: 0 PB Ratio: 3.69 GF Score: 58/100

Kiniksa Pharmaceuticals Ltd Rilonacept Analyst Day Transcript

Sep 29, 2020 / 12:00PM GMT
Release Date Price: $15.55 (+0.84%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Rilonacept Analyst Day conference call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)

I would now like to hand the conference to your speaker today, Mr. Mark Ragosa, Head of Investor Relations. Thank you. Please go ahead.

Mark Ragosa
Kiniksa Pharmaceuticals, Ltd. - Senior VP & CFO

Good morning, and thank you for joining Kiniksa's webcast covering the burden and unmet need of recurrent pericarditis as well as the potential for rilonacept to treat patients suffering from the disease and our strategy to bring this treatment to patients. The information we present today can be found through the investors and media section of our website.

Turning to the agenda. Our CEO, Sanj Patel, will start with an introduction. We'll also hear a first-hand account of the patient journey and learn more about the burden of recurrent pericarditis, the current treatment paradigm and the unmet need from Dr. Paul Cremer of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot